Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 264-267

  Bermúdez Humarán, Luis G ^a  

^a CEMAGREF   (France)

Author keywords

Antigens; Cytokines; Lactic acid bacteria; Lactococcus lactis; Mucosal vaccines

Indexed keywords

ANTIGEN; BACTERIAL VECTOR; INTERLEUKIN 10; NAKED DNA; PROTEIN E7; TETANUS FRAGMENT C; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; DAIRY INDUSTRY; FERMENTED PRODUCT; GENE VECTOR; GENETIC ENGINEERING; IMMUNIZATION; IMMUNOGENICITY; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; MUCOSAL IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NOTE; UTERINE CERVIX CANCER;

CLINICAL TRIALS AS TOPIC; CROHN DISEASE; GENETIC VECTORS; HUMANS; INTERLEUKIN-10; LACTOCOCCUS LACTIS; PROTEINS;

EID: 67649621174     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7553     Document Type: Note

References (40)

1. Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998; 351:1375-6.
2. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
3. Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001; 51:21-42.
4. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:45-53.
5. Cesta MF. Normal structure, function and histology of mucosa-associated lymphoid tissue. Toxicol Pathol 2006; 34:599-608.
6. Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008; 52:2-12.
7. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175:7297-302.
8. Shanley JD, Wu CA. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine 2005; 23:996-1003.
9. Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005; 65:6990-9.
10. Singh M, Chakrapani A, O'Hagan D, Wendorf J, Chesko J, Kazzaz J, et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin 2008; 4:44-9.
11. Hu KF, Lövgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001; 51:149-59.
12. Mielcarek N, Alonso S, Locht C. Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 2001; 51:55-69.
13. Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 2007; 6:97-110.
14. Alexandersen S. Advantages and disadvantages of using live vaccines risks and control measures. Acta Vet Scand Suppl 1996; 90:89-100.
15. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008; 6:349-62.
16. Bermúdez-Humarán LG, Corthier G, Langella P. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res Devel Microbiology 2004; 8:147-60.
17. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005; 68:705-17.
18. Iwaki M, Okahashi N, Takahashi I, Kanamoto T, Sugita-Konishi Y, Aibara K, et al. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect Immun 1990; 58:2929-34.
19. Wells JM, Wilson PW, Norton PM, Gasson MJ, Le Page RW. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 1993; 8:1155-62.
20. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997; 15:653-7.
21. Norton PM, Wells JM, Brown HW, Macpherson AM, Le Page RW. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 1997; 15:616-9.
22. Enouf V, Langella P, Commissaire J, Cohen J, Corthier G. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001; 7:1423-8.
23. Bermúdez-Humarán LG, Langella P, Miyoshi A, Gruss A, Guerra RT, Montes de Oca-Luna R, Le Loir Y. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 2002; 68:917-22.
24. Ribeiro LA, Azevedo V, Le Loir Y, Oliveira SC, Dieye Y, Piard JC, et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 2002; 68:910-6.
25. Miyoshi A, Bermúdez-Humarán LG, Ribeiro LA, Le Loir Y, Oliveira SC, Langella P, et al. Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis. Microb Cell Fact 2006; 5:14.
26. Bermúdez-Humarán LG, Rihakova J, Langella P, Demnerova K, Nazef L, Prévost H, Drider D. Antimicrobial activity of divercin RV41 produced and secreted by Lactococcus lactis. J Mol Microbiol Biotechnol 2007; 13:259-63.
27. Chatel JM, Langella P, Adel-Patient K, Commissaire J, Wal JM, Corthier G. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immunol 2001; 8:545-51.
28. Bermúdez-Humarán LG, Langella P, Commissaire J, Gilbert S, Le Loir Y, L'Haridon R, et al. Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis. FEMS Microbiol Lett 2003; 224:307-13.
29. Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003; 71:1887-96.
30. Bermúdez-Humarán LG, Cortes-Perez NG, L'Haridon R, Langella P. Production of biological active murine IFNgamma by recombinant Lactococcus lactis. FEMS Microbiol Lett 2008; 280:144-9.
31. Cortes-Perez NG, Medina LF, Lefèvre F, Langella P, Bermúdez-Humarán LG. Production of biologically active CXC chemokines by Lactococcus lactis: Evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine 2008; 26:5778-83.
32. Bermúdez-Humarán LG, Nouaille S, Zilberfarb V, Corthier G, Gruss A, Langella P, et al. Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight and immune response of mice. Appl Environ Microbiol 2007; 73:5300-7.
33. Bermúdez-Humarán LG, Cortes-Perez NG, Le Loir Y, Alcocer-González JM, Tamez-Guerra RS, de Oca-Luna RM, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004; 53:427-33.
34. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289:1352-5.
35. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:754-9.
36. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785-9.
37. Chatel JM, Pothelune L, Ah-Leung S, Corthier G, Wal JM, Langella P. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther 2008; 15:1184-90.
38. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 2007; 119:952-9.
39. Yuvaraj S, Lahham S, Marreddy RK, Dijkstra G, Wolken WA, Lolkema JS, et al. Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease. Mol Nutr Food Res 2008; 52:913-20.
40. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 2003; 100:11672-7.